Lipids
[Lipids]
EPTIS factsheet 142485 | Last revision 2024-12-20 | URL: https://www.eptis.bam.de/pts142485 https://www.eptis.bam.de/pts142485
| PT provider | ||||||||||||||||||||||||||||
| PT provider | Weqas Weqas | |||||||||||||||||||||||||||
| Based in | United Kingdom | |||||||||||||||||||||||||||
| Language(s) | ||||||||||||||||||||||||||||
| Remarks | Measurement of lipids and lipoproteins is primarily used to estimate the risk of atherosclerotic cardiovascular disease and guide therapeutic decision-making (ESC/EAS 2019), and as part of the identification and management of patients with familial hypercholesterolaemia (NICE CG71). The Lipid Programme includes all routinely monitored analytes for the screening, diagnosis and management of dyslipidaemias by the clinical laboratory, covering all the measured and calculated parameters. Forty frozen endogenous (single or pooled) human serum samples and eight fresh single donor samples are distributed annually. Reference target values using a CRML laboratory is provided for TC, TG, and HDL-C. A wide clinically relevant range is distributed, along with samples with high TG concentration to challenge the TC and LDL-C methods. The programme assesses both laboratory and method performance, including bias, within and between batch imprecision. Trueness is also assessed for a number of analytes using high metrological order Reference measurement systems. A less rigorous separate programme is provided for POCT sites undertaking healthcare screening. Key Features: - Liquid human serum samples requiring no prior preparation. - Commutable single and pooled donor samples. - Lipid profile includes all routinely monitored analytes and calculated parameters. - CDC reference values provided for Cholesterol, and HDL. - Traceable IDGCMS values provided for Cholesterol, Triglyceride and HDL. - Sigma metric scoring based on clinically relevant Milan Model 2 performance specification. For more information: https://www.weqas.com/services/eqa/Lipids/ or contact@weqas.com | |||||||||||||||||||||||||||
| Keywords | ||||||||||||||||||||||||||||
| Product groups |
Health care / medical devices
|
|||||||||||||||||||||||||||
| Testing fields |
Medical analysis
|
|||||||||||||||||||||||||||
| Technical details | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Aims of the PT scheme | ||||||||||||||||||||||||||||
| Target group of participants | The programme assesses both laboratory and method performance, including bias, within and between batch imprecision. | |||||||||||||||||||||||||||
| Linked to specific legislation / standards | Accreditation by UKAS on the basis of ISO/IEC 17043 | |||||||||||||||||||||||||||
| Additional, subsidiary aims | validation of testing methods | |||||||||||||||||||||||||||
| Number of participants | ||||||||||||||||||||||||||||
| Accredited or otherwise reviewed by a 3rd party |
Accredited by UKAS on the basis of ISO/IEC 17043 |
|||||||||||||||||||||||||||
| Operation is commissioned / requested by | ||||||||||||||||||||||||||||
| Fees and frequency | ||||||||||||||||||||||||||||
| Participation fee | Fee dependent on number of participating sections and proximetry of testing methods. | |||||||||||||||||||||||||||
| Regularly operated | Yes (Frequency: Monthly. Samples: 4 x 1.0mL. ) | |||||||||||||||||||||||||||
| Year of first operation | 1968 | |||||||||||||||||||||||||||
| Contact details of the PT provider | ||||||||||||||||||||||||||||
| Provider | Contact person | |||||||||||||||||||||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Phone: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884 Fax: Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
|||||||||||||||||||||||||||
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.